Comparative efficacy of novobiocin and amoxicillin in experimental sepsis caused by beta-lactam-susceptible and highly resistant pneumococci.
Rodríguez-Cerrato
Violeta
V
Department of Molecular Microbiology and Infection Biology, Centro de Investigaciones Biológicas (CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain. vrodriguez@cib.csic.es
Del Prado
Gema
G
Huelves
Lorena
L
Naves
Plínio
P
Ruiz
Vicente
V
García
Ernesto
E
Ponte
Carmen
C
Soriano
Francisco
F
D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D024881:Drug Resistance, Bacterial; D005260:Female; D051379:Mice; D008826:Microbial Sensitivity Tests; D050296:Microbial Viability / Q000187:drug effects; D009675:Novobiocin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010537:Peritoneum / Q000382:microbiology; D011008:Pneumococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D018805:Sepsis / Q000188:drug therapy* / Q000382:microbiology; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000201:enzymology; D016019:Survival Analysis; D016896:Treatment Outcome; D047090:beta-Lactams / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D047090:beta-Lactams; D009675:Novobiocin; D000658:Amoxicillin